Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
70 results about "Insulin-Like Growth Factor Receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A protein found on the surface of some types of cells that binds to insulin-like growth factor (IGF). This causes the cells to grow and divide. Insulin-like growth factor receptor is found at high levels on the surface of several types of cancer cells, which causes these cells to grow rapidly in the presence of IGF.
Anti-IGF-I receptor antibody
InactiveUS20050249728A1Increase profitOrganic active ingredientsFungiSynovial sarcomaAbnormal tissue growth
Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit, insulin-like growth factor-I receptor, antagonize the effects of IGF-I, IGF-II and serum on the growth and survival of tumor cells, and which are substantially devoid of agonist activity. Said antibodies and fragments thereof may be used, optionally in conjunction with other therapeutic agents, in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma, prostate cancer and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.
Owner:IMMUNOGEN INC
Antibodies to insulin-like growth factor I receptor
Owner:AMGEN FREMONT INC +1
Anti-IGF-I receptor antibody
Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit, insulin-like growth factor-I receptor, antagonize the effects of IGF-I, IGF-II and serum on the growth and survival of tumor cells, and which are substantially devoid of agonist activity. Said antibodies and fragments thereof may be used, optionally in conjunction with other therapeutic agents, in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma, prostate cancer and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.
Owner:IMMUNOGEN INC
Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
InactiveUS20130084243A1High affinityUseful in detectionAnimal cellsIn-vivo radioactive preparationsDiseaseSingle-Chain Antibodies
The present invention relates to mammalian antibodies, designated 12B1 and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR. Also included are chimeric, bispecific, derivatized, single chain antibodies derived from the antibodies disclosed herein. Nucleic acid molecules encoding the mammalian antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of IGf-1R.
Owner:GOETSCH LILIANE +4
Insulin and IGF-1 receptor agonists and antagonists
Peptide sequences capable of binding to insulin and / or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics.
Owner:NOVO NORDISK AS +1
Isulin and IGF-1 receptor agonists and antagonists
Peptide sequences capable of binding to insulin and / or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
Owner:NOVO NORDISK AS +1
Anti-IGF-I receptor antibody
InactiveUS7538195B2Increase profitOrganic active ingredientsFungiInsulin-like growth factorSynovial sarcoma
Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.
Owner:IMMUNOGEN INC
Insulin and IGF-1 receptor agonists and antagonists
Peptide sequences capable of binding to insulin and / or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
Owner:NOVO NORDISK AS +1
Insulin and IGF-1 receptor agonists and antagonists
InactiveUS6875741B2Peptide/protein ingredientsGenetic material ingredientsBinding sitePancreatic hormone
Peptide sequences capable of binding to insulin and / or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
Owner:NOVO NORDISK AS +1
Insulin and IGF-1 Receptor Agonists and Antagonists
Owner:NOVO NORDISK AS +1
Antibodies to insulin-like growth factor I receptor
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and / or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.
Owner:AMGEN FREMONT INC +1
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
ActiveUS8470332B2Reduce activationDistribution morePeptide/protein ingredientsAntibody mimetics/scaffoldsReceptorTyrosine
The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.
Owner:BRISTOL MYERS SQUIBB CO
Anti-IGF-1R antibodies and uses thereof
ActiveUS7612178B2Reduce dwell timeHigh binding affinityAnimal cellsSugar derivativesNucleotideWilms' tumor
Owner:BIOGEN MA INC
Insulin-like growth factor-1 receptor (IGF-1R) polymorphic alleles and use of the same to identify DNA markers for reproductive longevity
Disclosed herein are embodiments for genotyping an animal for the presence of polymorphic alleles in the IGF-1R gene that are associated with reproductive longevity and / or ability to better sustain stress, and preferably selecting those animals for future breeding purposes.
Owner:PERFORMANCE GENOMICS
IGF-IR antagonists as adjuvants for treatment of prostate cancer
InactiveUS20090175868A1Inhibits and prevents transitionBiocideOrganic active ingredientsCancer cellAdjuvant
The present invention relates to a method of treating prostate cancer with androgen deprivation therapy and an insulin-like growth factor receptor (IGF-IR) antagonist. Although the response rate of prostate cancer to androgen deprivation therapy (ADT) is high, surviving cancer cells invariably become androgen independent (AI) and tumor growth follows. The invention inhibits or delays transition of androgen dependent cancer to androgen independent cancer, significantly decreases risk of recurrence, and improves treatment outcome.
Owner:UNIV OF WASHINGTON +1
Neutralizing human anti-IGFR antibody
The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.
Owner:MERCK SHARP & DOHME CORP
Antibodies against insulin-like growth factor I receptor and uses thereof
InactiveUS20080014203A1Prolongates time to progressionSlow tumor growthAnimal cellsImmunoglobulins against growth factorsLactoseSugar
An antibody binding to IGF-IR, being of human IgG1 or IgG3 type and being glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 98%, and in addition the amount of NGNA is 1% or less and / or the amount of N-terminal alpha-1,3-galactose is 1% or less has improved properties in antitumor therapy.
Owner:F HOFFMANN LA ROCHE & CO AG
Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
A method of inhibiting the growth of hormone dependent tumor cells in a mammal comprises administering to said mammal an insulin-like growth factor receptor (IGF-IR) recombinant antibody, wherein said antibody can be a single-chain recombinant antibody, which can be humanized, capable of blocking agonist interaction with the IGF-IR.
Owner:CITY OF HOPE
Anti-IGF-1R antibodies and uses thereof
InactiveCN101842117AAntibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsInsulinlike growth factorWilms' tumor
The invention relates to antibodies which bind to insulin like growth factor receptor -1 (IGF-IR) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-lR-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies capable of synergistically inhibiting the ability of the ligands, insulin like growth factor 1 (IGF-I) and insulin like growth factor 2 (IGF-2), to bind to IGF-IR; as well as fragments, variants and derivatives of such antibodies. Antibodies of the invention produce such synergistic effects via allosteric and / or competitive inhibition of IGF-IR ligand binding.
Owner:BIOGEN MA INC
Methods and compositions for treating cancers using antisense
The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.
Owner:THOMAS JEFFERSON UNIV
Human Monoclonal Antibodies that Specifically Bind Igf-II
InactiveUS20080193465A1Inhibit phosphorylationImmunoglobulins against growth factorsDrug compositionsPhosphorylationBound insulin
Disclosed herein are isolated monoclonal human antibodies that specifically binds insulin-like growth factor II (IGF-II) with an equilibrium dissociation constant (Kd) of 1 nM or less, wherein the antibody bind IGF-I with an equilibrium dissociation constant (Kd) of 1 mM or greater. The antibodies inhibit phosphorylation of the insulin-like growth factor receptor. Nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and isolated host cells that express the nucleic acids are also disclosed. The antibodies can be used to detect human IGF-II in a sample. Methods of diagnosing a tumor are disclosed herein that utilize these antibodies. Methods of treating a subject with a tumor are also disclosed.
Owner:US DEPT OF HEALTH & HUMAN SERVICES
Long-acting insulin analogue preparations in soluble and crystalline forms
InactiveUS20130085101A1Enhances receptor-binding selectivityDecrease absolute affinity for IGF-1ROrganic active ingredientsBacteriaInsulin A ChainPharmaceutical formulation
A pharmaceutical formulation comprises an insulin analogue or a physiologically acceptable salt thereof, wherein the insulin analogue or a physiologically acceptable salt thereof contains an insulin A-chain sequence that contains paired Histidine substitutions at A4 and A8, and optionally a substitution at A21. The formulation further contains a pharmaceutically acceptable buffer containing at least about 4 zinc ions per 6 insulin analogue molecules. The formulation forms a long-acting zinc-dependent subcutaneous depot upon subcutaneous injection. In a zinc-free formulation, the insulin analogue monomer exhibits decreased affinity for the Insulin-like Growth Factor receptor and at least 20% of the affinity for the insulin receptor of the same species, in comparison to an otherwise identical insulin or insulin analogue that does not contain the HisA4 and HisA8 substitutions.
Owner:CASE WESTERN RESERVE UNIV
Modulation of insulin like growth factor i receptor expression
InactiveUS20060234239A1Modulate expressionOrganic active ingredientsBiocideGrowth Factor GeneInflammatory dermatosis
The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human IGF-IR. Such compounds are exemplified herein to modulate proliferation which is relevant to the treatment of proliferative and inflammatory skin disorders and cancer. It will be understood, however, that the compounds can be used for any other condition in which the IGF-IR is involved including inflammatory conditions.
Owner:ANTISENSE THERAPEUTICS LTD
Insulin and IGF-1 receptor agonists and antagonists
Peptide sequences capable of binding to insulin and / or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
Owner:NOVO NORDISK AS +1
Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
InactiveUS20100215573A1High affinityUseful in detectionAnimal cellsIn-vivo radioactive preparationsDiseaseSingle-Chain Antibodies
The present invention relates to mammalian antibodies, designated 12B1 and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR. Also included are chimeric, bispecific, derivatized, single chain antibodies derived from the antibodies disclosed herein. Nucleic acid molecules encoding the mammalian antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of IGf-1R.
Owner:MERCK SHARP & DOHME CORP +1
Neutralizing human anti-IGFR antibody
The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.
Owner:MERCK SHARP & DOHME CORP
Pyrrolidine[3,4-d]pyrimidine derivative and preparation method and application thereof
ActiveCN102584828AHas inhibitory activityInhibit phosphorylationOrganic active ingredientsOrganic chemistryDiseasePyrrolidine
The invention discloses a pyrrolidine[3,4-d]pyrimidine derivative and a preparation method and an application thereof. The pyrrolidine[3,4-d]pyrimidine derivative is an inhibitor of a type I insulin-like growth factor receptor (IGF-1R), and has a good IGF-1R inhibiting function and a good cancer cell proliferation inhibiting function, so that the pyrrolidine[3,4-d]pyrimidine derivative can be taken as a therapeutic agent for treating tumors and relevant diseases.
![Pyrrolidine[3,4-d]pyrimidine derivative and preparation method and application thereof](https://images-eureka.patsnap.com/patent_img/671d9e23-170c-4868-872a-2931bf254bbc/HSA00000419601900011.PNG "Pyrrolidine[3,4-d]pyrimidine derivative and preparation method and application thereof")
![Pyrrolidine[3,4-d]pyrimidine derivative and preparation method and application thereof](https://images-eureka.patsnap.com/patent_img/671d9e23-170c-4868-872a-2931bf254bbc/BSA00000419601800021.PNG "Pyrrolidine[3,4-d]pyrimidine derivative and preparation method and application thereof")
![Pyrrolidine[3,4-d]pyrimidine derivative and preparation method and application thereof](https://images-eureka.patsnap.com/patent_img/671d9e23-170c-4868-872a-2931bf254bbc/BSA00000419601800022.PNG "Pyrrolidine[3,4-d]pyrimidine derivative and preparation method and application thereof")
Owner:SHANGHAI ALLIST PHARM CO LTD
Insulin and IGF-1 receptor agonists and antagonists
Peptide sequences capable of binding to insulin and / or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics.
Owner:NOVO NORDISK AS +1
Methods and compositions for treating cancers using antisense
ActiveUS20180201939A1Prevent regenerationOptimal anti-tumor responseOrganic active ingredientsSpecial deliveryCancer cellGlioblastoma
The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.
Owner:THOMAS JEFFERSON UNIV
Combination therapy for neoplasia treatment
InactiveUS20140255413A1Improve the level ofOrganic active ingredientsImmunoglobulins against growth factorsInsulin-like growth factorPROSTATE NEOPLASIA
The present invention relates to an insulin-like growth factor (IGF) receptor antagonist for use in the treatment of prostate neoplasia, including benign prostatic hyperplasia (BPH), prostate cancer, and particularly CRPC, wherein the antagonist is used in combination with an androgen receptor antagonist. An embodiment of the invention is where the androgen receptor antagonist is enzalutamide.
Owner:BOEHRINGER INGELHEIM INT GMBH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com